Agios Pharmaceuticals (NASDAQ:AGIO) Insider James William Burns Sells 3,280 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider James William Burns sold 3,280 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $113,848.80. Following the transaction, the insider directly owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ:AGIO opened at $34.80 on Tuesday. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -4.89 and a beta of 0.79. The company has a 50-day moving average price of $29.00 and a 200-day moving average price of $32.12. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP raised its holdings in Agios Pharmaceuticals by 31.4% in the second quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after purchasing an additional 163,796 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Agios Pharmaceuticals in the third quarter worth $2,696,000. HighVista Strategies LLC raised its holdings in Agios Pharmaceuticals by 178.5% in the third quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock worth $7,839,000 after purchasing an additional 125,171 shares in the last quarter. Frazier Life Sciences Management L.P. increased its stake in shares of Agios Pharmaceuticals by 19.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock valued at $42,565,000 after purchasing an additional 209,900 shares in the last quarter. Finally, Boothbay Fund Management LLC increased its stake in shares of Agios Pharmaceuticals by 71.1% during the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock valued at $14,868,000 after purchasing an additional 185,798 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on AGIO. Citigroup upped their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Leerink Partners upped their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 1st. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $42.67.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (maintaining a “neutral” rating), signaling modest analyst upside and providing some support for the share price. Article Link
• Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29, 2026 — a standard corporate update that can trigger short-term moves around results but is informational until the release. Press Release
• Neutral Sentiment: Insider sale — Tsveta Milanova sold 3,262 shares at ~$34.71 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting; trade reduces her holdings ~6.5% but was routine and pre-planned. SEC Filing
• Neutral Sentiment: Insider sale — CFO Cecilia Jones sold 3,141 shares at ~$34.71 via a Rule 10b5-1 plan to cover taxes on vested awards; holding reduced ~5.4%. Investors typically view such planned tax-related sales as neutral. SEC Filing
• Neutral Sentiment: Insider sale — Sarah Gheuens sold 2,940 shares at ~$34.71 under a pre-arranged plan to cover tax withholding; position decreased ~3.5%. SEC Filing
• Neutral Sentiment: Insider sale — James William Burns sold 3,280 shares at ~$34.71 via a Rule 10b5-1 plan to cover tax obligations; holdings down ~6.2%. SEC Filing

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.